Biofrontera Inc. reported a significant improvement in its gross margin for Q1 2026, driven by a strategic transaction with Biofrontera AG.
Revenue increased 17% year-over-year to $10.1 million. Despite an operating loss, the net loss per share improved compared to the prior year.
In premarket trading, the stock fell 2.9%, extending a challenging week that saw shares drop 15.8%. The stock currently trades at $0.96. Bond.az analysis suggests the company remains undervalued relative to its Fair Value.
Despite recent weakness, shares surged 68% year-to-date, reflecting growing investor confidence in restructuring efforts.
